Viridian Therapeutics, Inc.
VRDNHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Viridian Therapeutics, Inc. (VRDN) is listed under Biotechnology. Valued at $1.99B, VRDN is a small-cap name in its sector. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.
Market Cap
$1.99B
Beta
0.90
P/E (TTM)
—
P/E (Fwd)
-6.85
EPS (TTM)
$-3.35
EPS (Fwd)
$-2.63
ROE
-58.1%
ROA
-33.3%
Cash
$762.2M
Total Debt
$53.4M
Free CF
-$182.6M
52W Change
9.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $762.2M in cash comfortably exceeding the $53.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$182.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -58.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $1.8M to $70.8M.
With cash comfortably exceeding debt, VRDN has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VRDN.